Among patients receiving BRAF ± MEKi therapy, 37 patients (15 female, 22 male) developed a CR (8.0% of all advanced melanoma patients receiving BRAF ± MEKi therapy) and were enrolled into this retrospective study (Figure 1). This evidence concerns the gene BRAF and melanoma.